Peptide Mainstreaming

Holdings

1. Eli Lilly LLY · Lead therapeutics 30%

   Tirzepatide already monetizes peptide demand, while retatrutide and newer incretins extend the category into broader metabolic care.

2. Novo Nordisk NVO · Peptide therapeutics 25%

   Semaglutide spans diabetes, obesity, and oral delivery, making Novo a direct read-through on peptide medicine becoming routine.

3. Amgen AMGN · Long-acting peptides 20%

   MariTide offers less-frequent dosing and multiple Phase 3 obesity studies, giving Amgen meaningful upside if convenience broadens adoption.

4. Hims & Hers HIMS · Consumer distribution 15%

   Its platform turns peptide interest into prescriptions, fulfillment, and ongoing support as consumers move from wellness curiosity to managed treatment.

5. Thermo Fisher TMO · Research and manufacturing 10%

   Its research and bioprocessing platform supplies picks and shovels, with less pure peptide exposure than the drugmakers.